Switch to:
Also traded in: Argentina, Austria, Brazil, Chile, France, Germany, Mexico, Romania, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.48
MRK's Cash-to-Debt is ranked lower than
67% of the 799 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.05 vs. MRK: 0.48 )
Ranked among companies with meaningful Cash-to-Debt only.
MRK' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.29  Med: 0.73 Max: N/A
Current: 0.48
Equity-to-Asset 0.43
MRK's Equity-to-Asset is ranked lower than
79% of the 731 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. MRK: 0.43 )
Ranked among companies with meaningful Equity-to-Asset only.
MRK' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.34  Med: 0.45 Max: 0.53
Current: 0.43
0.34
0.53
Interest Coverage 10.10
MRK's Interest Coverage is ranked lower than
74% of the 632 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 112.31 vs. MRK: 10.10 )
Ranked among companies with meaningful Interest Coverage only.
MRK' s Interest Coverage Range Over the Past 10 Years
Min: 4.14  Med: 10.18 Max: 20.13
Current: 10.1
4.14
20.13
Piotroski F-Score: 8
Altman Z-Score: 3.36
Beneish M-Score: -2.65
WACC vs ROIC
7.20%
10.87%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 18.29
MRK's Operating Margin % is ranked higher than
73% of the 758 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.95 vs. MRK: 18.29 )
Ranked among companies with meaningful Operating Margin % only.
MRK' s Operating Margin % Range Over the Past 10 Years
Min: 6.43  Med: 16.53 Max: 21.86
Current: 18.29
6.43
21.86
Net Margin % 12.71
MRK's Net Margin % is ranked higher than
67% of the 759 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.06 vs. MRK: 12.71 )
Ranked among companies with meaningful Net Margin % only.
MRK' s Net Margin % Range Over the Past 10 Years
Min: 1.87  Med: 13.05 Max: 47.03
Current: 12.71
1.87
47.03
ROE % 12.32
MRK's ROE % is ranked higher than
62% of the 780 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.91 vs. MRK: 12.32 )
Ranked among companies with meaningful ROE % only.
MRK' s ROE % Range Over the Past 10 Years
Min: 1.51  Med: 11.48 Max: 42.27
Current: 12.32
1.51
42.27
ROA % 5.30
MRK's ROA % is ranked higher than
54% of the 805 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.71 vs. MRK: 5.30 )
Ranked among companies with meaningful ROA % only.
MRK' s ROA % Range Over the Past 10 Years
Min: 0.79  Med: 5.9 Max: 16.34
Current: 5.3
0.79
16.34
ROC (Joel Greenblatt) % 50.42
MRK's ROC (Joel Greenblatt) % is ranked higher than
80% of the 793 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.48 vs. MRK: 50.42 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
MRK' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 10.88  Med: 44.45 Max: 105.49
Current: 50.42
10.88
105.49
3-Year Revenue Growth Rate -0.90
MRK's 3-Year Revenue Growth Rate is ranked lower than
72% of the 634 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.10 vs. MRK: -0.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
MRK' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -16.5  Med: 8.4 Max: 22.8
Current: -0.9
-16.5
22.8
3-Year EBITDA Growth Rate -4.50
MRK's 3-Year EBITDA Growth Rate is ranked lower than
74% of the 601 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.90 vs. MRK: -4.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
MRK' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -17.6  Med: 8.1 Max: 44.8
Current: -4.5
-17.6
44.8
3-Year EPS without NRI Growth Rate -1.40
MRK's 3-Year EPS without NRI Growth Rate is ranked lower than
62% of the 576 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.60 vs. MRK: -1.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
MRK' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -29.3  Med: 12.2 Max: 73.8
Current: -1.4
-29.3
73.8
GuruFocus has detected 6 Warning Signs with Merck & Co Inc $MRK.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» MRK's 30-Y Financials

Financials (Next Earnings Date: 2017-10-25 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

MRK Guru Trades in Q3 2016

Tweedy Browne 3,306 sh (New)
Jeremy Grantham 7,500 sh (New)
Steven Cohen 179,800 sh (New)
Stanley Druckenmiller 683,800 sh (New)
Eaton Vance Worldwide Health Sciences Fund 247,081 sh (New)
Paul Tudor Jones 612,800 sh (+15612.82%)
David Carlson 275,000 sh (+10.00%)
Ken Fisher 6,817,544 sh (+0.86%)
David Dreman 710 sh (unchged)
First Eagle Investment 7,790 sh (unchged)
Robert Bruce 259,400 sh (unchged)
Tom Gayner 5,600 sh (unchged)
Murray Stahl 45,497 sh (unchged)
Ruane Cunniff Sold Out
Ray Dalio Sold Out
Signature Select Canadian Fund Sold Out
Jeff Auxier 153,153 sh (-0.10%)
PRIMECAP Management 2,964,300 sh (-0.11%)
John Buckingham 25,560 sh (-0.45%)
Richard Pzena 1,408,678 sh (-0.47%)
Kahn Brothers 957,991 sh (-0.72%)
Charles Brandes 2,812,318 sh (-2.75%)
T Rowe Price Equity Income Fund 3,375,000 sh (-3.57%)
Mairs and Power 96,933 sh (-5.12%)
Mario Gabelli 107,405 sh (-5.37%)
Richard Snow 792,347 sh (-6.64%)
Vanguard Health Care Fund 41,516,228 sh (-10.72%)
Manning & Napier Advisors, Inc 335,976 sh (-16.92%)
Dodge & Cox 18,327,311 sh (-24.80%)
Barrow, Hanley, Mewhinney & Strauss 18,581,032 sh (-29.93%)
Pioneer Investments 602,479 sh (-33.20%)
Joel Greenblatt 330,785 sh (-38.77%)
Jim Simons 1,303,400 sh (-55.46%)
» More
Q4 2016

MRK Guru Trades in Q4 2016

Jeremy Grantham 13,700 sh (+82.67%)
John Buckingham 31,185 sh (+22.01%)
Manning & Napier Advisors, Inc 379,630 sh (+12.99%)
Murray Stahl 47,880 sh (+5.24%)
Mairs and Power 97,839 sh (+0.93%)
Pioneer Investments 606,522 sh (+0.67%)
Jeff Auxier 153,453 sh (+0.20%)
David Dreman 710 sh (unchged)
T Rowe Price Equity Income Fund 3,375,000 sh (unchged)
First Eagle Investment 7,790 sh (unchged)
Robert Bruce 259,400 sh (unchged)
Tom Gayner 5,600 sh (unchged)
Stanley Druckenmiller 683,800 sh (unchged)
David Carlson 275,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 247,081 sh (unchged)
Tweedy Browne Sold Out
Steven Cohen Sold Out
Jim Simons Sold Out
PRIMECAP Management 2,959,100 sh (-0.18%)
Ken Fisher 6,802,264 sh (-0.22%)
Kahn Brothers 952,741 sh (-0.55%)
Mario Gabelli 106,605 sh (-0.74%)
Charles Brandes 2,690,441 sh (-4.33%)
Barrow, Hanley, Mewhinney & Strauss 17,668,105 sh (-4.91%)
Richard Pzena 1,260,853 sh (-10.49%)
Joel Greenblatt 287,063 sh (-13.22%)
Vanguard Health Care Fund 35,181,618 sh (-15.26%)
Dodge & Cox 13,947,142 sh (-23.90%)
Richard Snow 407,174 sh (-48.61%)
Paul Tudor Jones 9,900 sh (-98.38%)
» More
Q1 2017

MRK Guru Trades in Q1 2017

Tweedy Browne 3,306 sh (New)
Steven Cohen 155,000 sh (New)
Jim Simons 7,363,034 sh (New)
Caxton Associates 7,900 sh (New)
Signature Select Canadian Fund 33,950 sh (New)
Paul Tudor Jones 168,527 sh (+1602.29%)
Joel Greenblatt 767,331 sh (+167.30%)
PRIMECAP Management 4,875,300 sh (+64.76%)
John Buckingham 32,088 sh (+2.90%)
Manning & Napier Advisors, Inc 383,314 sh (+0.97%)
Ken Fisher 6,862,961 sh (+0.89%)
T Rowe Price Equity Income Fund 3,375,000 sh (unchged)
First Eagle Investment 7,790 sh (unchged)
Robert Bruce 259,400 sh (unchged)
Tom Gayner 5,600 sh (unchged)
David Carlson 275,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 247,081 sh (unchged)
David Dreman Sold Out
Stanley Druckenmiller Sold Out
Mario Gabelli 105,805 sh (-0.75%)
Kahn Brothers 940,119 sh (-1.32%)
Pioneer Investments 597,088 sh (-1.56%)
Dodge & Cox 13,689,174 sh (-1.85%)
Jeff Auxier 149,153 sh (-2.80%)
Charles Brandes 2,606,115 sh (-3.13%)
Murray Stahl 46,324 sh (-3.25%)
Mairs and Power 90,144 sh (-7.86%)
Vanguard Health Care Fund 32,271,044 sh (-8.27%)
Barrow, Hanley, Mewhinney & Strauss 15,815,276 sh (-10.49%)
Richard Snow 318,316 sh (-21.82%)
Richard Pzena 826,233 sh (-34.47%)
Jeremy Grantham 7,600 sh (-44.53%)
» More
Q2 2017

MRK Guru Trades in Q2 2017

Ray Dalio 13,227 sh (New)
Stanley Druckenmiller 755,500 sh (New)
Pioneer Investments 690,621 sh (+15.66%)
Manning & Napier Advisors, Inc 441,029 sh (+15.06%)
John Buckingham 36,755 sh (+14.54%)
Caxton Associates 9,000 sh (+13.92%)
Murray Stahl 49,262 sh (+6.34%)
PRIMECAP Management 5,111,500 sh (+4.84%)
Ken Fisher 7,100,308 sh (+3.46%)
Jeff Auxier 149,213 sh (+0.04%)
Tom Gayner 5,600 sh (unchged)
David Carlson 275,000 sh (unchged)
Mario Gabelli 105,805 sh (unchged)
First Eagle Investment 7,790 sh (unchged)
Robert Bruce 259,400 sh (unchged)
Tweedy Browne 3,306 sh (unchged)
Steven Cohen 550,000 sh (unchged)
T Rowe Price Equity Income Fund 3,370,700 sh (-0.13%)
Richard Pzena 824,940 sh (-0.16%)
Kahn Brothers 932,840 sh (-0.77%)
Dodge & Cox 13,557,699 sh (-0.96%)
Barrow, Hanley, Mewhinney & Strauss 15,542,519 sh (-1.72%)
Mairs and Power 85,121 sh (-5.57%)
Vanguard Health Care Fund 30,067,944 sh (-6.83%)
Steven Cohen 132,300 sh (-14.65%)
Charles Brandes 2,190,048 sh (-15.97%)
Jeremy Grantham 6,300 sh (-17.11%)
Jim Simons 4,592,134 sh (-37.63%)
Joel Greenblatt 120,462 sh (-84.30%)
Paul Tudor Jones 8,940 sh (-94.70%)
Richard Snow 5,327 sh (-98.33%)
Eaton Vance Worldwide Health Sciences Fund 136,719 sh (-44.67%)
» More
» Details

Insider Trades

Latest Guru Trades with MRK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2017-06-30 Reduce -6.83%0.31%$61.89 - $66.16 $ 61.49-4%30,067,944
Barrow, Hanley, Mewhinney & Strauss 2017-06-30 Reduce -1.72%0.03%$61.89 - $66.16 $ 61.49-4%15,542,519
Dodge & Cox 2017-06-30 Reduce -0.96%0.01%$61.89 - $66.16 $ 61.49-4%13,557,699
Ken Fisher 2017-06-30 Add 3.46%0.02%$61.89 - $66.16 $ 61.49-4%7,100,308
T Rowe Price Equity Income Fund 2017-06-30 Reduce -0.13%$61.89 - $66.16 $ 61.49-4%3,370,700
Charles Brandes 2017-06-30 Reduce -15.97%0.39%$61.89 - $66.16 $ 61.49-4%2,190,048
Kahn Brothers 2017-06-30 Reduce -0.77%0.08%$61.89 - $66.16 $ 61.49-4%932,840
Richard Pzena 2017-06-30 Reduce -0.16%$61.89 - $66.16 $ 61.49-4%824,940
Joel Greenblatt 2017-06-30 Reduce -84.30%0.52%$61.89 - $66.16 $ 61.49-4%120,462
Vanguard Health Care Fund 2017-03-31 Reduce -8.27%0.41%$59.92 - $66.58 $ 61.49-3%32,271,044
Barrow, Hanley, Mewhinney & Strauss 2017-03-31 Reduce -10.49%0.16%$59.92 - $66.58 $ 61.49-3%15,815,276
Dodge & Cox 2017-03-31 Reduce -1.85%0.01%$59.92 - $66.58 $ 61.49-3%13,689,174
Ken Fisher 2017-03-31 Add 0.89%0.01%$59.92 - $66.58 $ 61.49-3%6,862,961
Charles Brandes 2017-03-31 Reduce -3.13%0.07%$59.92 - $66.58 $ 61.49-3%2,606,115
Kahn Brothers 2017-03-31 Reduce -1.32%0.13%$59.92 - $66.58 $ 61.49-3%940,119
Richard Pzena 2017-03-31 Reduce -34.47%0.14%$59.92 - $66.58 $ 61.49-3%826,233
Joel Greenblatt 2017-03-31 Add 167.30%0.39%$59.92 - $66.58 $ 61.49-3%767,331
Mario Gabelli 2017-03-31 Reduce -0.75%$59.92 - $66.58 $ 61.49-3%105,805
Tweedy Browne 2017-03-31 New Buy0.01%$59.92 - $66.58 $ 61.49-3%3,306
David Dreman 2017-03-31 Sold Out 0.02%$59.92 - $66.58 $ 61.49-3%0
Vanguard Health Care Fund 2016-12-31 Reduce -15.26%0.85%$58.43 - $64.96 $ 61.490%35,181,618
Barrow, Hanley, Mewhinney & Strauss 2016-12-31 Reduce -4.91%0.09%$58.43 - $64.96 $ 61.490%17,668,105
Dodge & Cox 2016-12-31 Reduce -23.90%0.26%$58.43 - $64.96 $ 61.490%13,947,142
Ken Fisher 2016-12-31 Reduce -0.22%$58.43 - $64.96 $ 61.490%6,802,264
Charles Brandes 2016-12-31 Reduce -4.33%0.11%$58.43 - $64.96 $ 61.490%2,690,441
Richard Pzena 2016-12-31 Reduce -10.49%0.06%$58.43 - $64.96 $ 61.490%1,260,853
Kahn Brothers 2016-12-31 Reduce -0.55%0.06%$58.43 - $64.96 $ 61.490%952,741
Joel Greenblatt 2016-12-31 Reduce -13.22%0.04%$58.43 - $64.96 $ 61.490%287,063
Mario Gabelli 2016-12-31 Reduce -0.74%$58.43 - $64.96 $ 61.490%106,605
Tweedy Browne 2016-12-31 Sold Out 0.01%$58.43 - $64.96 $ 61.490%0
Vanguard Health Care Fund 2016-09-30 Reduce -10.72%0.61%$57.65 - $63.86 $ 61.490%41,516,228
Barrow, Hanley, Mewhinney & Strauss 2016-09-30 Reduce -29.93%0.7%$57.65 - $63.86 $ 61.490%18,581,032
Dodge & Cox 2016-09-30 Reduce -24.80%0.34%$57.65 - $63.86 $ 61.490%18,327,311
Ken Fisher 2016-09-30 Add 0.86%0.01%$57.65 - $63.86 $ 61.490%6,817,544
T Rowe Price Equity Income Fund 2016-09-30 Reduce -3.57%0.03%$57.65 - $63.86 $ 61.490%3,375,000
Charles Brandes 2016-09-30 Reduce -2.75%0.07%$57.65 - $63.86 $ 61.490%2,812,318
Richard Pzena 2016-09-30 Reduce -0.47%$57.65 - $63.86 $ 61.490%1,408,678
Kahn Brothers 2016-09-30 Reduce -0.72%0.08%$57.65 - $63.86 $ 61.490%957,991
Joel Greenblatt 2016-09-30 Reduce -38.77%0.14%$57.65 - $63.86 $ 61.490%330,785
Mario Gabelli 2016-09-30 Reduce -5.37%$57.65 - $63.86 $ 61.490%107,405
Tweedy Browne 2016-09-30 New Buy0.01%$57.65 - $63.86 $ 61.490%3,306
Ruane Cunniff 2016-09-30 Sold Out $57.65 - $63.86 $ 61.490%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:NYSE:PFE, NYSE:ABBV, NYSE:BMY, NYSE:LLY, NAS:AERI, AMEX:TXMD, NAS:RTRX, NAS:RMTI, NAS:ZGNX, NAS:ALIM, AMEX:NNVC, NAS:PRPH, AMEX:AXN, NAS:TNXP, OTCPK:INNV, NAS:ALQA, NAS:IMNP, OTCPK:INBP, OTCPK:ENZB, NYSE:JNJ » details
Traded in other countries:MRK.Argentina, MRK.Austria, MRCK34.Brazil, MRK.Chile, MRK.France, 6MK.Germany, MRK.Mexico, MRK.Romania, MRK.Switzerland, 0QAH.UK,
Headquarter Location:USA
Merck & Co Inc is a health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiovascular disease, asthma, cancer, and infections. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. From a geographical perspective, close to half of the company's sales are generated in the United States.

Top Ranked Articles about Merck & Co Inc

Vanguard Sells Medtronic, Cigna in 2nd Quarter Largest sales of the most recent quarter
Vanguard Health Care Fund (Trades, Portfolio) owns a portfolio composed of 74 stocks with a total value of $46.532 billion. During the second quarter the guru sold shares in the following stocks: Read more...
US Market Indexes Lower With Geopolitical Concerns Dow Jones falls to 22,085.34
U.S. market indexes were lower Tuesday. Read more...
Tech Stocks Lower on Thursday Dow Jones closes at 21796.55
U.S. market indexes were mostly lower Thursday. Read more...
Mandy Moore and Merck Encourage Women to Plan Ahead in Her Life. Her Adventures. Campaign
US Market Indexes Lower on Thursday General Electric leads losses
U.S. market indexes were lower on Thursday. Read more...
Spring Bank Pharmaceuticals' Hepatitis B Results in Context Here's a look at where the company's latest data fit into the hepatitis B space as a whole
Spring Bank Pharmaceuticals Inc. (NASDAQ:SBPH) announced positive initial Phase II results for its new antiviral hepatitis B (HBV) treatment SB-9200. Shares have recorded all-time highs, up as much as 28% on the news. Read more...
Edward Owens Buys Abbott Labs, Sells Allergan, Amgen, Aetna Vanguard Health Care Fund's largest 1st-quarter trades
Edward Owens has managed the Vanguard Health Care Fund (Trades, Portfolio) since its inception in May 1984. It invests primarily in health care companies. Read more...
Osteoporosis Drug Meets Primary and Secondary Endpoints But researchers observe a higher rate of serious cardiovascular adverse events
Amgen Inc. (NASDAQ:AMGN) informed the stock market through the PRNewswire May 21 about the results of the ARCH clinical trial, Phase 3, with which Evenity (romosozumab) – an investigational monoclonal antibody that increases bone formation – was assessed in postmenopausal women affected with osteoporosis and who have a high risk of fracture. Evenity is aimed to prevent fractures in these patients. Read more...
Howard Marks on the Truth About Investing The value investor discusses the best ways to invest
Howard Marks (Trades, Portfolio) is one of Wall Street’s most astute value investors. He is known in the investment community for his Oaktree memos to clients, which detail investment strategies and insights on the economy. These memos are always highly informative as Marks has an unrivaled view of Wall Street. His Oaktree Capital invests in distressed assets, the very essence of value investing, and in 2008, Oaktree raised $10.9 billion from investors, making it the largest distressed-debt fund in history. Oaktree’s 17 distressed debt funds have achieved annualized returns of 19% per annum after fees for the past 22 years. Read more...
US Market Indexes Higher on Thursday Stocks regain some ground lost due to political concerns
U.S. market indexes regained some of their losses from political worries on Thursday. Read more...

Ratios

vs
industry
vs
history
PE Ratio 33.42
MRK's PE Ratio is ranked lower than
70% of the 555 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.93 vs. MRK: 33.42 )
Ranked among companies with meaningful PE Ratio only.
MRK' s PE Ratio Range Over the Past 10 Years
Min: 6.33  Med: 22.43 Max: 138.33
Current: 33.42
6.33
138.33
Forward PE Ratio 15.85
MRK's Forward PE Ratio is ranked higher than
63% of the 67 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 18.90 vs. MRK: 15.85 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 33.42
MRK's PE Ratio without NRI is ranked lower than
70% of the 554 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.21 vs. MRK: 33.42 )
Ranked among companies with meaningful PE Ratio without NRI only.
MRK' s PE Ratio without NRI Range Over the Past 10 Years
Min: 6.33  Med: 22.43 Max: 138.33
Current: 33.42
6.33
138.33
Price-to-Owner-Earnings 41.08
MRK's Price-to-Owner-Earnings is ranked lower than
81% of the 303 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.90 vs. MRK: 41.08 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
MRK' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 6.35  Med: 16.75 Max: 84.71
Current: 41.08
6.35
84.71
PB Ratio 4.26
MRK's PB Ratio is ranked lower than
71% of the 751 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.80 vs. MRK: 4.26 )
Ranked among companies with meaningful PB Ratio only.
MRK' s PB Ratio Range Over the Past 10 Years
Min: 1.72  Med: 3.24 Max: 7.25
Current: 4.26
1.72
7.25
PS Ratio 4.26
MRK's PS Ratio is ranked lower than
64% of the 736 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.97 vs. MRK: 4.26 )
Ranked among companies with meaningful PS Ratio only.
MRK' s PS Ratio Range Over the Past 10 Years
Min: 2.01  Med: 3.37 Max: 5.48
Current: 4.26
2.01
5.48
Price-to-Free-Cash-Flow 20.00
MRK's Price-to-Free-Cash-Flow is ranked lower than
51% of the 208 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.89 vs. MRK: 20.00 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
MRK' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.88  Med: 16.53 Max: 88.07
Current: 20
7.88
88.07
Price-to-Operating-Cash-Flow 16.70
MRK's Price-to-Operating-Cash-Flow is ranked lower than
54% of the 277 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.02 vs. MRK: 16.70 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
MRK' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.68  Med: 14.15 Max: 35.61
Current: 16.7
6.68
35.61
EV-to-EBIT 27.00
MRK's EV-to-EBIT is ranked lower than
73% of the 559 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.11 vs. MRK: 27.00 )
Ranked among companies with meaningful EV-to-EBIT only.
MRK' s EV-to-EBIT Range Over the Past 10 Years
Min: 4.9  Med: 17.8 Max: 52.5
Current: 27
4.9
52.5
EV-to-EBITDA 15.89
MRK's EV-to-EBITDA is ranked higher than
50% of the 587 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.50 vs. MRK: 15.89 )
Ranked among companies with meaningful EV-to-EBITDA only.
MRK' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.2  Med: 9.6 Max: 20.4
Current: 15.89
4.2
20.4
Shiller PE Ratio 27.65
MRK's Shiller PE Ratio is ranked higher than
65% of the 198 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 39.37 vs. MRK: 27.65 )
Ranked among companies with meaningful Shiller PE Ratio only.
MRK' s Shiller PE Ratio Range Over the Past 10 Years
Min: 8.27  Med: 16.96 Max: 29.99
Current: 27.65
8.27
29.99
Current Ratio 1.50
MRK's Current Ratio is ranked lower than
69% of the 782 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.40 vs. MRK: 1.50 )
Ranked among companies with meaningful Current Ratio only.
MRK' s Current Ratio Range Over the Past 10 Years
Min: 0.97  Med: 1.51 Max: 3.7
Current: 1.5
0.97
3.7
Quick Ratio 1.21
MRK's Quick Ratio is ranked lower than
64% of the 782 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.82 vs. MRK: 1.21 )
Ranked among companies with meaningful Quick Ratio only.
MRK' s Quick Ratio Range Over the Past 10 Years
Min: 0.69  Med: 1.19 Max: 3.44
Current: 1.21
0.69
3.44
Days Inventory 154.16
MRK's Days Inventory is ranked lower than
65% of the 707 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 117.36 vs. MRK: 154.16 )
Ranked among companies with meaningful Days Inventory only.
MRK' s Days Inventory Range Over the Past 10 Years
Min: 108.49  Med: 130.49 Max: 205.16
Current: 154.16
108.49
205.16
Days Sales Outstanding 69.68
MRK's Days Sales Outstanding is ranked higher than
59% of the 651 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 74.70 vs. MRK: 69.68 )
Ranked among companies with meaningful Days Sales Outstanding only.
MRK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 44.5  Med: 59.4 Max: 87.87
Current: 69.68
44.5
87.87
Days Payable 83.43
MRK's Days Payable is ranked lower than
53% of the 600 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 70.96 vs. MRK: 83.43 )
Ranked among companies with meaningful Days Payable only.
MRK' s Days Payable Range Over the Past 10 Years
Min: 37.12  Med: 47.38 Max: 90.81
Current: 83.43
37.12
90.81

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 3.04
MRK's Dividend Yield % is ranked higher than
79% of the 691 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.23 vs. MRK: 3.04 )
Ranked among companies with meaningful Dividend Yield % only.
MRK' s Dividend Yield % Range Over the Past 10 Years
Min: 2.51  Med: 3.61 Max: 6.68
Current: 3.04
2.51
6.68
Dividend Payout Ratio 1.01
MRK's Dividend Payout Ratio is ranked higher than
56% of the 406 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.33 vs. MRK: 1.01 )
Ranked among companies with meaningful Dividend Payout Ratio only.
MRK' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.27  Med: 0.85 Max: 5.43
Current: 1.01
0.27
5.43
3-Year Dividend Growth Rate 2.30
MRK's 3-Year Dividend Growth Rate is ranked lower than
62% of the 299 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.90 vs. MRK: 2.30 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
MRK' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 5 Max: 31
Current: 2.3
0
31
Forward Dividend Yield % 3.06
MRK's Forward Dividend Yield % is ranked higher than
75% of the 673 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. MRK: 3.06 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 3.54
MRK's 5-Year Yield-on-Cost % is ranked higher than
71% of the 821 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.11 vs. MRK: 3.54 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
MRK' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.92  Med: 4.21 Max: 7.78
Current: 3.54
2.92
7.78
3-Year Average Share Buyback Ratio 2.10
MRK's 3-Year Average Share Buyback Ratio is ranked higher than
97% of the 473 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.10 vs. MRK: 2.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MRK' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -12.9  Med: 1 Max: 2.8
Current: 2.1
-12.9
2.8

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 33.73
MRK's Price-to-Tangible-Book is ranked lower than
97% of the 690 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.51 vs. MRK: 33.73 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
MRK' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.19  Med: 10.94 Max: 3112.5
Current: 33.73
3.19
3112.5
Price-to-Intrinsic-Value-Projected-FCF 1.45
MRK's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
67% of the 328 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.31 vs. MRK: 1.45 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
MRK' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.75  Med: 1.5 Max: 3.48
Current: 1.45
0.75
3.48
Price-to-Median-PS-Value 1.27
MRK's Price-to-Median-PS-Value is ranked lower than
67% of the 712 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.09 vs. MRK: 1.27 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
MRK' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.63  Med: 1.19 Max: 2.11
Current: 1.27
0.63
2.11
Price-to-Graham-Number 7.08
MRK's Price-to-Graham-Number is ranked lower than
95% of the 480 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.08 vs. MRK: 7.08 )
Ranked among companies with meaningful Price-to-Graham-Number only.
MRK' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.09  Med: 3.26 Max: 31.92
Current: 7.08
1.09
31.92
Earnings Yield (Greenblatt) % 3.70
MRK's Earnings Yield (Greenblatt) % is ranked higher than
50% of the 805 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. MRK: 3.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MRK' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.9  Med: 5.6 Max: 20.6
Current: 3.7
1.9
20.6
Forward Rate of Return (Yacktman) % 2.05
MRK's Forward Rate of Return (Yacktman) % is ranked lower than
65% of the 380 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.46 vs. MRK: 2.05 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
MRK' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -5.7  Med: 7.25 Max: 20.4
Current: 2.05
-5.7
20.4

More Statistics

Revenue (TTM) (Mil) $40,015.00
EPS (TTM) $ 1.84
Beta0.96
Short Percentage of Float0.55%
52-Week Range $58.29 - 66.80
Shares Outstanding (Mil)2,727.35

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 40,327 41,101 43,338
EPS ($) 3.88 4.24 4.78
EPS without NRI ($) 3.88 4.24 4.78
EPS Growth Rate
(Future 3Y To 5Y Estimate)
4.37%
Dividends per Share ($) 1.89 1.97 1.97
» More Articles for MRK

Headlines

Articles On GuruFocus.com
Vanguard Sells Medtronic, Cigna in 2nd Quarter Aug 17 2017 
US Market Indexes Lower With Geopolitical Concerns Aug 09 2017 
Tech Stocks Lower on Thursday Jul 28 2017 
Mandy Moore and Merck Encourage Women to Plan Ahead in Her Life. Her Adventures. Campaign Jul 27 2017 
What Financial Modeling Says About Gilead Sciences Jul 26 2017 
US Market Indexes Lower on Thursday Jul 10 2017 
VBI Vaccines Just Took a Major Step Forward in Its HBV Program Jun 21 2017 
DarioHealth: Disruption Is Valuable Jun 07 2017 
Spring Bank Pharmaceuticals' Hepatitis B Results in Context Jun 07 2017 
Edward Owens Buys Abbott Labs, Sells Allergan, Amgen, Aetna May 23 2017 

More From Other Websites
Opdivo Could Drive Bristol-Myers Squibb’s Revenue Growth in 2017 Aug 18 2017
Gilead (GILD) HCV Drug Vosevi Receives Approval in Canada Aug 18 2017
AstraZeneca/Merck's Lynparza Gets FDA Nod for Label Expansion Aug 18 2017
See what the IHS Markit Score report has to say about Merck & Co Inc. Aug 18 2017
Pharma Stock Roundup: Multiple Sclerosis Drug Prices in Focus, Mixed Data on BMY's Opdivo Aug 18 2017
[$$] Lost $12 Million Windfall Sparks Suit Against Delaware Aug 18 2017
Corporate America’s, Wall Street’s new mindset on Donald Trump Aug 18 2017
FDA expands use of AstraZeneca/Merck ovarian cancer drug Aug 17 2017
FDA approves expanded use of AstraZeneca ovarian cancer drug Aug 17 2017
LYNPARZA Receives Additional and Broad Approval in the U.S. for Ovarian Cancer Aug 17 2017
Eli Lilly: Will A New Rival Hobble Its Top Growth Driver? Aug 17 2017
Can Pfizer Bank on New Immunotherapy Bavencio for Growth? Aug 17 2017
Sanofi’s Revenue Growth in 2Q17 Aug 17 2017
Valeant's Papa: 'It's been a challenging 15 months, but w... Aug 16 2017
Valeant Pharmaceuticals CEO Joe Papa: 'It's been a challe... Aug 16 2017
Trump Council CEOs Had Been Pressured to Step Down For Months Aug 16 2017
CEO Timeline: Who Quit White House Councils When, And How Trump Reacted Aug 16 2017
JPMorgan CEO Jamie Dimon Issues Sharp Rebuke of Trump Aug 16 2017
All leaders have to speak to things that are right and wr... Aug 16 2017
Merck has more manufacturing employees in US than oversea... Aug 16 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}